Welcome to our dedicated page for NOVAVAX SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax director Richard J. Rodgers reported equity compensation activity and an RSU vesting-related exercise. On June 20, 2026, he exercised 18,880 restricted stock units into 18,880 shares of common stock, bringing his direct common stock holdings to 47,370 shares.
Two days earlier, on June 18, 2026, he received grants of 14,180 new RSUs and 21,270 stock options with a $9.13 exercise price, each tied to the company’s Amended and Restated 2015 Stock Incentive Plan. Both the new RSUs and options vest 100% on the first anniversary of the June 18, 2026 grant date, subject to continued board service. The RSU exercise reflects full vesting of a prior June 20, 2025 RSU grant.
Novavax director Rachel K. King reported equity compensation activity and no share sales. On June 20, 2026 she exercised 18,880 restricted stock units (RSUs), receiving 18,880 shares of common stock, bringing her direct common stock holdings to 44,070 shares.
On June 18, 2026 she received two new awards under Novavax’s Amended and Restated 2015 Stock Incentive Plan: 14,180 RSUs and a stock option for 21,270 shares of common stock at an exercise price of $9.13 per share. The footnotes state that 100% of the new RSUs and option shares will vest on the first anniversary of the June 18, 2026 grant date, subject to her continued service on the board.
Novavax director Richard Douglas reported equity compensation activity, not open-market trading. On June 20, 2026, he exercised 18,880 restricted stock units, receiving the same number of Novavax common shares at no cash cost, bringing his direct holdings to 73,220 shares.
On June 18, 2026, he was granted 14,180 new restricted stock units and a stock option for 21,270 shares with a $9.13 exercise price. Footnotes state that 100% of these RSUs and options vest on the first anniversary of the grant date, subject to his continued service on the board.
Novavax director Margaret G. McGlynn reported equity compensation and an option exercise. On June 18, 2026, she received 14,180 Restricted Stock Units (RSUs) and 21,270 stock options, each RSU and option tied to one share of common stock. The options have a $9.13 per-share exercise price and will fully vest on the first anniversary of the grant date, subject to her continued board service.
On June 20, 2026, previously granted RSUs covering 18,880 shares vested and were exercised into the same number of Novavax common shares, leaving no remaining RSUs from that 2025 grant. After these transactions, she directly holds 44,468 shares of Novavax common stock. All reported activity reflects equity awards and vesting rather than any open-market buying or selling.
Novavax director David M. Mott reported equity compensation and an RSU vesting event. On June 18, 2026, he received grants of 14,180 Restricted Stock Units and a stock option for 21,270 shares of common stock with a $9.13 exercise price. Both awards vest 100% on the first anniversary of the grant date, subject to his continued service on the Board.
On June 20, 2026, 18,880 previously granted RSUs fully vested and were converted into 18,880 shares of Novavax common stock. Following this conversion, he directly holds 79,770 shares of common stock. These transactions reflect compensation-related awards and an option-style RSU conversion, with no open-market buying or selling.
Novavax director Gregg H. Alton reported equity compensation activity and an RSU vesting that increased his direct common stock holdings. On June 18, 2026, he received grants of 21,270 stock options with a $9.13 exercise price and 14,180 restricted stock units, each unit representing one share of common stock.
The footnotes state that 100% of these awards will vest on the first anniversary of the June 18, 2026 grant date, subject to continued board service. On June 20, 2026, 18,880 RSUs from a prior grant vested and were converted into the same number of common shares, bringing his direct holdings to 47,685 shares. All transactions are compensation-related grants and exercises, not open‑market purchases or sales.
Novavax director John W. Shiver received new equity awards as part of his board compensation. On June 18, 2026, he was granted 14,180 restricted stock units, each representing one share of Novavax common stock. He was also granted stock options on 21,270 shares at an exercise price of $9.13 per share.
Both the RSUs and the options were awarded under Novavax’s Amended and Restated 2015 Stock Incentive Plan. According to the terms, all of the shares subject to each grant vest on the first anniversary of the June 18, 2026 grant date, if he continues serving on the board through that date.
NOVAVAX INC director Charles W. Newton received new equity awards as part of his compensation. On June 18, 2026, he was granted 14,180 restricted stock units, each representing one share of Novavax common stock, and a stock option for 21,270 shares at an exercise price of $9.13 per share.
According to the company’s Amended and Restated 2015 Stock Incentive Plan, one hundred percent of the option shares will vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service on the Board of Directors. The RSU grant is also described as vesting in full on the first anniversary of that grant date, under the same continued-service condition.
Novavax, Inc. reported the results of its annual stockholder meeting held on June 18, 2026. Stockholders owning 99,118,766 of 164,427,429 eligible common shares were present or represented by proxy, which was sufficient to conduct business.
Three Class I directors — John C. Jacobs, Gregg H. Alton, J.D., and Richard J. Rodgers — were elected to three-year terms expiring at the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of Novavax’s named executive officers and approved amendments and restatements to both the 2015 Stock Incentive Plan and the 2013 Employee Stock Purchase Plan.
In addition, stockholders ratified the appointment of Ernst & Young LLP as Novavax’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
NVAX filed a Form 144 reporting proposed resale activity tied to a stock plan on 05/27/2026. The filing lists that Ruxandra Draghia Akli sold 30,000 shares of Common Stock on 05/07/2026 and shows 296,083 shares in a related line of the filing.